MannKind Corporation, which is waiting for FDA approval of its Afrezza inhaled insulin, announced that it hopes to raise up to $110 million by lending 9 million shares of its stock to Bank of America. Merrill Lynch will then sell the borrowed shares, shorting the stock, and will use the proceeds in conjunction with a private offering of MannKind Senior Convertible Notes due in 2015. Read the company’s press release
MannKind announces $110 million stock agreement
published on
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA
